[Psychosomatic aspects of stress]

Area of Science:

• Neuroendocrinology
• Psychosomatic Medicine
• Dopaminergic Function Assessment

Background:

• The hypothalamopituitary axis plays a crucial role in stress response and hormonal regulation.
• Dopamine receptor agonists, like Bromocriptine, can modulate growth hormone (GH) and prolactin (PRL) secretion.
• Understanding dopaminergic function is key to diagnosing and treating psychosomatic disorders.

Observation:

• The Bromocriptine test classifies individuals into 'response' and 'non-response' types based on plasma GH and PRL secretion patterns.
• Response type individuals exhibit increased GH and suppressed PRL, correlating with neurotic/maladaptive behaviors under stress.
• Non-response type individuals show no significant GH change, correlating with alexithymic/over-adaptive behaviors under stress.

Findings:

• Response type cases were observed in essential hypertension, gastric ulcers, and technostress syndrome, linked to neurotic tendencies or technoanxiety.
• Non-response type cases were identified in essential hypertension (Type A behavior), gastric ulcers (over-adaptive behavior), and technostress syndrome (technodependent).
• Psychosomatic treatments varied, including psychotherapy, self-control training, autogenic training, and lifestyle adjustments, with fasting therapy noted to normalize a non-response pattern.

Implications:

• The Bromocriptine test offers a novel method for assessing dopaminergic function in the hypothalamopituitary gland.
• This test may help differentiate patient subgroups based on their behavioral responses to psychosocial stress.
• Findings suggest a link between dopaminergic function, stress coping mechanisms, and psychosomatic conditions, potentially guiding personalized treatment strategies.